Jaguar Health, Inc. and Napo Pharmaceuticals announced that Sandra M. Swain, MD, FACP, FASCO has joined the Jaguar/Napo Scientific Advisory Board (SAB). Dr. Swain is the Associate Dean for Research Development and Professor of Medicine at the Georgetown University Medical Center (GUMC) and the Vice President of Genetic Medicine for MedStar Health in Washington, DC. Previously she held leadership roles at the National Cancer Institute (NCI), National Institutes of Health (NIH) and the Washington Cancer Institute at MedStar Washington Hospital Center.

She has served on the Board of Directors for the American Society of Clinical Oncology (ASCO) and is a past President of ASCO (2012-2013. Dr. Swain is a fellow of the American College of Physicians and ASCO. She currently serves as a member of the board of Seagen and Conquer Cancer Foundation Board of ASCO and chairs the Women Who Conquer Cancer committee.

Dr. Swain has published more than 335 articles, many on clinical trials in breast cancer and is a Visiting Professor of Clinical Oncology in the Medical Sciences Division at the University of Oxford in the UK. Dr. Swain graduated with a Bachelor of Arts in Chemistry from the University of North Carolina and earned a Doctor of Medicine (M.D.) from the University of Florida. She completed her residency in Internal Medicine at Vanderbilt University and a fellowship in Medical Oncology at the NCI, NIH.

She has previously served as the Deputy Branch Chief for the Medicine Branch of the Center for Cancer Research at the NCI. She serves on the Executive Committee of the Georgetown Lombardi Comprehensive Cancer Center; actively participates in the NRG Breast Committee; and co-chairs the Early Breast Cancer Trialists' Collaborative Group Steering Committee, in Oxford, UK.